Could the world's best-selling drug have a protégé?
After months of crazy volatility, the stock seems to have made up its mind on which direction to go: up
Could Celgene's newest drug finally get this company the respect it deserves?
After a 60% increase since the start of 2017, can shares continue to move higher?
Does Zogenix stand a chance against the cannabis king?
Shares of Synergy are down, but things are looking up for this GI gem
June will be a pivotal month for shareholders of Portola Pharmaceuticals and Neos Therapeutics
Adamis is working on an EpiPen alternative, and the payoff could be huge
Biogen's "moonshot" will likely end in failure
Acadia Pharmaceuticals May Just Be the Best Long-Term Play on the Alzheimer's Disease Treatment Market
After a significant pullback in April, is now the right time to jump into Acadia?
A hedge fund founder and a once-failed drug are a recipe for disaster
A combination one-two punch has left investors cheering
After a slow start, are sales of Repatha finally about to pick up?
Will Sanofi acquire anything? Or is this deal smarter than it seems?
What lessons should investors learn from Ackman's greatest mistake?
After dropping more than 30% off its highs, is now the time to buy this baby biotech?
Will VenBio successfully negotiate a higher bid for IMMU-132?
Will shares move higher? Or will a boardroom battle leave this biotech cruising for a bruising?
After Years of Stagnation, Are Shares of Rigel Pharmaceuticals About to Take off Into the Stratosphere?
Beneath the surface, Rigel has been gearing up for an explosive 2017
This tiny biotech could be Alexion's worst nightmare